

Als Arzt in der Transfusionsmedizin in den USA Ein Erfahrungsbericht

- 1) Haspel, RL and Uhl, L (2012),
How do I audit hospital blood product utilization?
Transfusion, **52**: 227-230.
- 2) AABB (2011), *Standards for Blood Banks and Transfusion Services*, AABB, 27th Edition.
- 3) *Code of Federal Regulations, Title 21 (21CFR606.151)*.
- 4) Oberman, HA, (1992),
The present and future crossmatch.
Transfusion, Nov-Dec; **32(9)**:794-796.
- 5) Pinkerton, PH, Coovadia, AS and Goldstein, J (1992),
Frequency of delayed hemolytic transfusion reactions following antibody screening and immediate-spin crossmatching.
Transfusion, **32**: 814-817.
- 6) Schmidt, PJ (1989),
The algorithm and the crossmatch.
Transfusion, **29**: 95-96.
- 7) Meyer, EA and Shulman, IA (1989),
The sensitivity and specificity of the immediate-spin crossmatch.
Transfusion, **29**: 99-102.
- 8) McCullough, J, (2012)
Transfusion Medicine, Wiley-Blackwell, 3rd Edition. ISBN 978-1-4443-3705-1.
- 9) *Report of the US Department of Health and Human Services. The 2009 national blood collection and utilization survey report.*
Washington, DC: US Department of Health and Human Services, Office of the Assistant Secretary for Health, 2011.
ISBN 978-1-56395-328-6
<http://www.aabb.org/programs/biovigilance/nbcus/Documents/09-nbcus-report.pdf> (Zugriff auf Internet-Link am 30.07.2012).
- 10) <http://www.redcrossblood.org/hospitals/infectious-disease-testing> (Zugriff auf Internet-Link am 30.07.2012).
- 11) *FDA Guidance for Industry, 27, Mai 2010, Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products.*
- 12) *Bildnachweis: Dr. med. Ulrike F. Königbauer.*